Engineered immune cells take on liver cancer in new trial
NCT ID NCT06084884
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a therapy called AZD5851, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack liver cancer cells. The trial includes 94 adults with advanced or recurrent liver cancer that has not responded to standard treatments. Participants receive one infusion of these modified cells after a short course of chemotherapy to prepare their immune system. The main goals are to check safety and see if the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD5851 (a CAR-T cell therapy targeting GPC3)
What this could lead to
If it works, this could offer a new treatment option for people with advanced liver cancer that hasn't responded to other therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 94 participants, so results may not apply to everyone. CAR-T therapies can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Phoenix, Arizona, 85054, United States
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Orange, California, 92868, United States
-
Research Site
San Francisco, California, 94143, United States
-
Research Site
Washington D.C., District of Columbia, 20007, United States
-
Research Site
Jacksonville, Florida, 32224, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
Westwood, Kansas, 66205, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
Hackensack, New Jersey, 07601, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Portland, Oregon, 97239, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Pittsburgh, Pennsylvania, 15237, United States
-
Research Site
Kashiwa, 227-8577, Japan
-
Research Site
Osakasayama-shi, 589-8511, Japan
-
Research Site
Seoul, 03080, South Korea